Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Different TAK-994 Formulations
NCT04745767Phase 1Completed
- Sponsor
- Takeda
- Start
- Feb 2021
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of firazorexton in narcolepsy (3 arms), sponsored by Takeda. Primary endpoints: Maximum Observed Plasma Concentration at Day 1, Area Under the Plasma Concentration-time Curve From Time 0 to Last Quantifiable Concentration at Day 1 and 1 more. Started Feb 2021; status: completed.
02
Drugs
firazorexton
03
Conditions
narcolepsy
Beyond the preview
Go deeper on NCT04745767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04745767.